Takeda Pharmaceutical agreed to purchase Intellikine for $190 million upfront and an additional $120 million in milestone payments later. The acquisition gives Takeda access to Intellikine's small-molecule cancer drugs that inhibit many variations of the PI3 kinase pathway. INK218 and INK1117 have the potential to become best-in-class compounds among the drug candidates, Takeda said.

Full Story:

Related Summaries